<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393611</url>
  </required_header>
  <id_info>
    <org_study_id>1107011830</org_study_id>
    <nct_id>NCT03393611</nct_id>
  </id_info>
  <brief_title>CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage&#xD;
      therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or&#xD;
      refractory AML or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2012</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>100 days</time_frame>
    <description>Evaluate the time to neutrophil engraftment, defined as the first day in which absolute neutrophil count (ANC) &gt;500/mm3 for three consecutive days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival at Day 100, 6 months, and 1 year</measure>
    <time_frame>Day 100, 6 months, and 1 year post-transplant</time_frame>
    <description>Evaluate survival of subjects alive, with or without presence of disease, at the designated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Survival at Day 100, 6 months, and 1 year</measure>
    <time_frame>Day 100, 6 months, and 1 year post-transplant</time_frame>
    <description>Evaluate survival of subjects alive without disease at the designated time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse Mortality</measure>
    <time_frame>Day 100</time_frame>
    <description>Death that cannot be explained by persistence, relapse, or progression of underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>Day 100, 6 months, 1 year</time_frame>
    <description>Time to first relapse or progression of underlying disease after initiation of protocol therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Relapsed Adult Acute Myeloid</condition>
  <condition>Myelodysplastic Syndromes, Previously Treated</condition>
  <arm_group>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Cytarabine:Daunorubicin Liposome Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 (Day -2)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Anti-Human T-Lymphocyte Globulin</intervention_name>
    <description>Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo-Cord Stem Cell Transplantation</intervention_name>
    <description>Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must have refractory or relapsed Acute Myeloid Leukemia (AML) according to&#xD;
             previously established criteria:&#xD;
&#xD;
               1. Primary induction failure (PIF) after ≥ 2 cycles of chemotherapy&#xD;
&#xD;
               2. First relapse&#xD;
&#xD;
               3. Relapse refractory to salvage chemotherapy&#xD;
&#xD;
               4. Second or subsequent relapse&#xD;
&#xD;
          2. Subjects with Myelodysplastic Syndrome (MDS):&#xD;
&#xD;
             (a) Either Refractory Anemia with Excess Blasts I or Refractory Anemia with Excess&#xD;
             Blasts II (RAEB I or RAEB II)&#xD;
&#xD;
          3. Karnofsky performance status ≥ 70&#xD;
&#xD;
          4. Willing to participate as a research subject and sign an informed consent form&#xD;
&#xD;
          5. Adequate physical function measured by:&#xD;
&#xD;
               1. Cardiac: asymptomatic, or if symptomatic then Left Ventricular Ejection Fraction&#xD;
                  (LVEF) at rest must be ≥ 45% and must improve with exercise&#xD;
&#xD;
               2. Hepatic: ≤3 x upper limit of normal (ULN) alanine aminotransferase (ALT) and ≤&#xD;
                  1.5 total serum bilirubin, unless liver is involved with the disease or there is&#xD;
                  congenital benign hyperbilirubinemia&#xD;
&#xD;
               3. Renal: serum creatinine within normal range, or if serum creatinine is outside&#xD;
                  the normal range, then calculated creatinine clearance ≥ 60 ml/min&#xD;
&#xD;
               4. Pulmonary: asymptomatic, or if symptomatic, diffusing capacity of the lungs for&#xD;
                  carbon monoxide (DLCO) ≥ 45% of predicted (corrected for hemoglobin)&#xD;
&#xD;
          6. If subject has prior malignancy, must be without any evidence of disease of that prior&#xD;
             malignancy for at least 2 years (excludes skin cancers that may have been excised&#xD;
             within that 2 year period).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious active or uncontrolled infection or medical condition&#xD;
&#xD;
          2. Women who are pregnant or breast feeding. Women of childbearing age must use adequate&#xD;
             contraception and have a negative pregnancy test.&#xD;
&#xD;
          3. Prior daunorubicin therapy with a cumulative dose of more than 368 mg/m2 or equivalent&#xD;
&#xD;
          4. Other systemic anticancer therapy or ongoing clinically relevant toxicities from such&#xD;
             therapy (at discretion of the investigator)&#xD;
&#xD;
          5. History of and/or current evidence of myocardial impairment (e.g. cardiomyopathy,&#xD;
             ischemic heart disease, significant valvular dysfunction, hypertensive heart disease,&#xD;
             congestive heart failure), resulting in heart failure by New York Heart Association&#xD;
             Class III or IV staging.&#xD;
&#xD;
          6. Subjects with Wilson disease or other Copper-related disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen van Besien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

